

Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at www.bccancer.bc.ca and according to acceptable standards of care

PROTOCOL CODE: GIGAVCOXN

(Page 1 of 2)

DOCTOR'S ORDERS	Ht	cm	Wt	_kg BSA	m²	
REMINDER: Please ensure drug allergies and previous bleomycin are documented on the Allergy & Alert Form						
DATE: To be g	given:		Су	cle(s) #:		
Date of Previous Cycle:						
□ Delay treatment week(s) □ CBC & Diff, Platelets day of treatment May proceed with doses as written if within 96 hours ANC greater than or equal to 1.2 x 10 ⁹ /L, Platelets greater than or equal to 75 x 10 ⁹ /L, Creatinine Clearance greater than or equal to 50 mL/minute, creatinine less than or equal to 1.5 times the upper limit of normal and less than or equal to 1.5 times the baseline, ALT less than or equal to 3 times the upper limit of normal, bilirubin less than or equal to 1.5 times the upper limit of normal						
Dose modification for: Hematology Proceed with treatment based on blood work						
PREMEDICATIONS: Patient to take own sup						
ondansetron 8 mg PO prior to treatment dexamethasone 8 mg or 12 mg (circle one) PO NO ice chips For prior nivolumab infusion reaction: diphenhydrAMINE 50 mg PO 30 minutes prior acetaminophen 325 to 975 mg PO 30 minutes prior to	rior to treatme tes prior to tre	nt				
☐ Other:						
** Have Hypersensitivity Reaction Tray & Protocol Available**						
CHEMOTHERAPY: Repeat in three weeks						
nivolumab line to be primed with NS; oxaliplatin line to be primed with D5W						
nivolumab 4.5 mg/kg xkg = mg (max. 360 mg) IV in 50 to 100 mL NS over 30 minutes using a 0.2 micron in-line filter oxaliplatin 130 mg/m² x BSA = mg Dose Modification:mg/m² x BSA =mg IV in 250 to 500 mL D5W over 2 hours. Flush line with 25 mL D5W pre and post dose.						
To reduce incidence of vascular pain: 250 mL total volume of D5W to be administered concurrently with oxaliplatin at a maximum rate of 125 mL/h 500 mL total volume of D5W to be administered concurrently with oxaliplatin at a maximum rate of 250 mL/h						
capecitabine 1000 mg/m² or x BSA x (%) = mg PO BID x 14 days (refer to Capecitabine Suggested Tablet Combination Table for dose rounding)						
DOCTOR'S SIGNATURE:				SIGNATURE UC:	::	



Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at www.bccancer.bc.ca and according to acceptable standards of care

PROTOCOL CODE: GIGAVCOXN

(Page 2 of 2)

DATE:				
RETURN APPOINTMENT ORDERS				
Return in three weeks for Doctor and Cycle Return in six weeks for Doctor and Cycle & Book chemo x 2 cycles Last Cycle. Return in week(s)				
CBC and diff, platelets, creatinine, alkaline phosphatase, ALT, total bilirubin, LDH, sodium, potassium, magnesium, calcium, TSH prior to each cycle				
If clinically indicated: ☐ CEA ☐ CA 19-9 ☐ ECG ☐ Chest X-ray <u>or</u> ☐ CT Chest ☐ Free T3 and free T4 ☐ lipase ☐ morning serum cortisol ☐ Glucose				
☐ serum ACTH levels ☐ testosterone ☐ estradiol ☐ FSH ☐ LH				
☐ serum HCG or ☐ urine HCG – required for woman of child bearing potential				
☐ INR weekly ☐ INR prior to each cycle				
☐ Radiologic evaluation				
☐ Weekly nursing assessment				
☐ Other consults:				
☐ See general orders sheet for additional requests.				
DOCTOR'S SIGNATURE:	SIGNATURE:			
	UC:			